Arcellx (ACLX) Depreciation & Amortization (CF) (2021 - 2025)
Arcellx's (ACLX) quarterly Depreciation & Amortization (CF) came in at $1.6 million in Q4 2025, down 8.27% year-on-year from $1.8 million in Q4 2024, and down 10.96% quarter-over-quarter from $1.8 million in Q3 2025.
Arcellx (ACLX) Depreciation & Amortization (CF) (2021 - 2025) Analysis & Trends
Arcellx's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $1.6 million for Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) fell 8.27% year-over-year to $1.6 million in Q4 2025; TTM through Dec 2025 was $6.7 million, a 28.72% increase from a year earlier, with the FY2025 full-year figure at $6.7 million, up 28.72% from the prior year.
- Depreciation & Amortization (CF) slipped to $1.6 million in Q4 2025 per ACLX's latest filing, from $1.8 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.8 million in Q3 2025 and bottomed at $207000.0 in Q1 2021.
- The 5-year median for Depreciation & Amortization (CF) is $443000.0 (2023), against an average of $813400.0.
- Across the five-year window, Depreciation & Amortization (CF) soared 198.43% in 2024 and slipped 8.27% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $331000.0 in 2021, then gained by 25.68% to $416000.0 in 2022, then soared by 73.56% to $722000.0 in 2023, then surged by 147.78% to $1.8 million in 2024, then slipped by 8.27% to $1.6 million in 2025.
- Per Business Quant, the three latest ACLX Depreciation & Amortization (CF) figures stand at $1.6 million (Q4 2025), $1.8 million (Q3 2025), and $1.6 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 1.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.64 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.58 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Mar 31, 2024 | 826,000.00 |
| Mar 31, 2024 | 826,000.00 |
| Dec 31, 2023 | 722,000.00 |
| Dec 31, 2023 | 722,000.00 |
| Sep 30, 2023 | 447,000.00 |
| Sep 30, 2023 | 447,000.00 |